Wendy S. Rubinstein, MD, PhD, FACMG, FACP, Joins CancerLinQ LLC as Division Director, Clinical Data Management and Curation



Wendy S. Rubinstein, MD, PhD, FACMG, FACP

Wendy S. Rubinstein, MD, PhD, FACMG, FACP

CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has -announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. 

Dr. Rubinstein will oversee the team working to securely process and analyze the -CancerLinQ® platform’s patient data from millions of electronic health records to give personalized insights that can improve the quality of care for patients with cancer.

Dr. Rubinstein will direct all clinical data quality and data curation efforts for the rapidly growing CancerLinQ® database, which currently includes practices in 40 states and the District of Columbia, and CancerLinQ Discovery™—anonymized, statistically deidentified, fit-for-purpose clinical data sets derived from the CancerLinQ® platform to support hypothesis-based research.

Prior to joining CancerLinQ LLC, Dr. Rubinstein held several roles at the National Institutes of Health (NIH), including Senior Scientist; Chief, Medical Genetics and Human Variation National Center for Biotechnology Information; and Director, NIH Genetic Testing Registry. Before leading at NIH, Dr. Rubinstein spent more than a decade at NorthShore University HealthSystem’s Evanston Hospital—a CancerLinQ® vanguard practice—as Chief of the Division of Genetics and Director of the Center for Medical Genetics. She also has served as Clinical Associate Professor of Medicine at the University of Chicago Pritzker School of Medicine and Adjunct Associate Professor of Medicine at Northwestern University.

Dr. Rubinstein, who has published extensively in peer-reviewed journals, holds certification from the American Board of Internal Medicine and dual board certification in clinical genetics and clinical molecular genetics from the American Board of Medical Genetics. Dr. Rubinstein has an MD from the Mount Sinai School of Medicine (now the Icahn School of Medicine at Mount Sinai), a PhD in biomedical sciences from The City University of New York, and a BA in biochemistry from Brandeis University.

CancerLinQ® is a powerful platform containing growing amounts of real-world cancer information. This national initiative will allow cancer providers to improve the quality and value of their care by analyzing millions of cancer patient medical records, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines. ■ 

© 2017. American Society of Clinical Oncology. All rights reserved. 



Advertisement

Advertisement



Advertisement

click me